Keyword: Seamus Fernandez
If recent numbers—and a new doctor survey—are any indication, Tesaro's Zejula has the lead in ovarian cancer. But that could change.
Merck’s cholesterol med anacetrapib delivered a surprise win in its cardiovascular outcomes trial. Did it win big enough to make a launch worthwhile?
Analysts recently sized up Bristol-Myers as a takeover target. Now, word has it that Roche, Novartis and Pfizer are actively looking at a buy. But a megamerger? That's the question.